Vascularized Islet Cell Implant Device for T1D Therapy Avoids Systemic Immunosuppression
A coin-sized implantable device created by scientists at Houston Methodist Research…
U.S. FDA Approves CARVYKTI™ (ciltacabtagene autoleucel), Janssen’s First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
HORSHAM, Pa., February 28, 2022 – The Janssen Pharmaceutical Companies of…
